Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5760-5766

  Kuznetsov, Galina ^a   Towle, Murray J ^a   Cheng, Hongsheng ^a   Kawamura, Takanori ^b   TenDyke, Karen ^a   Liu, Diana ^a   Kishi, Yoshito ^a   Yu, Melvin J ^a   Littlefield, Bruce A ^a  

^a EISAI RESEARCH INSTITUTE   (United States)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE ORANGE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYTOCHROME C; E 7389; ETHIDIUM BROMIDE; HALICHONDRIN B; KETONE DERIVATIVE; LIPOCORTIN 5; MACROCYCLIC COMPOUND; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; TUBULIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL MEMBRANE; CELL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; MITOSIS SPINDLE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CASPASE 3; CASPASE 9; CASPASES; CELL LINE, TUMOR; CELL MEMBRANE; CELL POLARITY; CYTOCHROMES C; DIPLOIDY; ENZYME ACTIVATION; ETHERS, CYCLIC; FURANS; G2 PHASE; HUMANS; KETONES; MALE; MITOCHONDRIA; MITOSIS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; U937 CELLS;

EID: 4143052665     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1169     Document Type: Article

References (48)

1. Uemura D, Takahashi K, Yamamoto T, et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985;107:4796-8.
2. Hirata Y, Uemura D. Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58:701-10.
3. Bai R, Paull K, Herald C, Malspeis L, Pettit G, Hamel E. Halichondrin B and homohalichondrin B marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991;266:15882-9.
4. Ludueña R, Roach M, Prasad V, Pettit G. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 1993;45:421-7.
5. Bai R, Cichacz Z, Herald C, Pettit G, Hamel E. Spongistatin 1 a highly cytotoxic sponge-derived marine natural product that inhibits mitosis microtubule assembly and the binding of vinblastine to tubulin. Mol Pharmacol 1993;44:757-66.
6. Hamel E. Natural products which interact with tubulin in the vinca domain maytansine rhizoxin phomopsin A dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992;55:31-51.
7. Aicher T, Buszek K, Fang F, et al. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992;114:3162-4.
8. Kishi Y, Fang FG, Forsyth C, Scola P, Yoon S. Halichondrins and related compounds. Washington, DC: U.S. Patent Office; 1995: U.S. Patent 5,436,238.
9. Stamos D, Sean S, Kishi Y. New synthetic route to the C14-C38 segment of halichondrins. J Org Chem 1997;62:7552-3.
10. Wang Y, Habgood G, Christ W, Kishi Y, Littlefield B, Yu M. Structure-activity relationships of halichondrin B analogues modifications at C30-C38. Bioorg Med Chem Lett 2000;10:1029-32.
11. Towle M, Salvato K, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21.
12. Littlefield B, Palme M, Seletsky B, Towle M, Yu M, Zheng W. Macrocyclic analogs and methods of their use and preparation. Washington, DC: U.S. Patent Office; 2001: U.S. Patent 6,214,865.
13. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
14. Nicoletti I, Migliorati G, Pagliacci M, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Immunol Methods 1991;139:271-9.
15. Goto H, Tomono Y, Ajiro K, et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 1999;274:25543-9.
16. Mantel CR, Gelfano VM, Kim YJ, et al. P21waf-1-Chk1 pathway monitors G1 phase microtubule integrity and is crucial for restriction point transition. Cell Cycle 2002;1:327-36.
17. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001;20:3806-13.
18. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-6.
19. Duke R, Cohen J. Morphological and biochemical assays of apoptosis. Curr Prot Immunol 1992;13:1713-6.
20. Mukhopadhyay D, Sundereshan S, Rao C, Karande A. Placental protein 14 induces apoptosis in T cells but not in monocytes. J Biol Chem 2001;276:28268-73.
21. Koopman G, Reutelingsperger C, Kuijten G, Keehnen R, Pals S, VanOers M. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.
22. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
23. Blagosklonny M, Giannakakou P, El-Deiry W, et al. Raf-1/bcl-2 phosphorylation a step from microtubule damage to cell death. Cancer Res 1997;57:130-5.
24. Halder S, Basu A, Croce C. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
25. Wang L, Liu XM, Kreis W, Budman D. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44:355-61.
26. Srivastava R, Mi Q, Hardwick J, Longo D. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999;96:3775-80.
27. Yamamoto K, Ichijo H, Korsmeyer S. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 1999;19:8469-78.
28. Liu X, Kim C, Yang J. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome C. Cell 1996;86:147-57.
29. Kluck R, Bossy-Wetzel E, Green D, Newmeyer D. The release of cytochrome C from mitochondria a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
30. Zou H, Li Y, Liu X, Wang X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-56.
31. Saleh A, Srinivasula S, Acharya S, Fishel R, Alnemri E. Cytochrome C and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999;274:17941-5.
32. Thornberry N, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
33. Salvesen G, Dixit V. Caspases: intracellular signaling by proteolysis. Cell 1997;91:443-6.
34. Kuida K. Caspase-9. Int J Biochem Cell Biol 2000;32:121-4.
35. Portera A, Jänicke R. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999;6:99-104.
36. Ozoren N, Kim K, Burns T, Dicker D, Moscioni A, El-Deiry W. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000;60:6259-65.
37. Kaufmann S, Desnoyers S, Ottaviano Y, Davidson N, Poirer G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976-85.
38. Smulson M, Simbulan-Rosenthal C, Boulares A, et al. Roles of poly(ADP-ribosyl) ation and PARP in apoptosis, DNA repair, genomic stability, and functions of p53 and E2F-1. Adv Enzyme Regul 2000;40:183-215.
39. Towle MJ, Salvato KA, Budrow J, et al. In vivo anticancer activity of synthetic halichondrin B macrocyclic ketone analogs ER-076349 and ER-086526 correlates with ability to induce irreversible mitotic blocks [abstract]. Proc Am Assoc Cancer Res 2001;42:367.
40. Fan M, Du L, Stone A, Gilbert K, Chambers T. Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2-M. Cancer Res 2000;60:6403-7.
41. Bergamaschi D, Ronzoni S, Taverna S, et al. Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound. Br J Cancer 1999;79:267-77.
42. Haldar S, Jena N, Croce C. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-11.
43. Haldar S, Chintapalli J, Croce C. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
44. Blagosklonny M. Unwinding the loop of Bcl-2 phosphorylation. Leukemia 2001;15:869-74.
45. Haldar S, Basu A, Croce C. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
46. Blagosklonny M, Bishop P, Robey RT, Bates S. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res 2000;60:3425-8.
47. Blagosklonny MV, Robey R, Sheikh MS, Fojo T. Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther 2002;1:113-7.
48. Broker LE, Huisman C, Ferreira CG, Rodriguez JA, Kruyt FA, Giaccone G. Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer Res 2002;62:4081-8.